White Papers & Published Articles

Before the industry was talking about hyperoxaluria or enzymes, our Captozyme team was busy researching, writing, and publishing our scientific breakthroughs. Using articles and white papers, we have shared our expertise with the world to help move the microbiome movement forward.

Cowley et al-1.jpg

In vitro and in vivo safety evaluation of Nephure

Nephure™ is a proprietary oxalate decarboxylase (OxDC) enzyme being developed as a food ingredient. In this study, the safety of Nephure™ was evaluated in a bacterial mutagenicity assay and in a subchronic (13-week) oral toxicity study in rats. Nephure™ did not show any mutagenic properties in the mutagenicity assay.

Screen Shot 2018-10-11 at 2.19.25 PM.png

open-label in-house study with Nephure

Enzymatic interception of dietary oxalate in the stomach can help people maintain a low oxalate diet, without having to actively avoid oxalate containing food and beverages. An open-label, in-house clinical study was conducted by Captozyme where all participants were either employees or family members committed to advancing the standard of care. 


World congress of endourology abstract

In September 2018, an abstract and poster featuring Captozyme and our A0 research were presented at the 2018 World Congress of Endourology in Paris. The abstract on Reduction of Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate explored the potential development of an oral agent utilizing A0 to intercept oxalate in both the stomach (diet) and the intestines (endogenous).